{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jimenez Jimenez AM"],"funding":["NIAID NIH HHS","NHLBI NIH HHS","NCI NIH HHS"],"pagination":["3068-3077"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8758206"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["56(12)"],"pubmed_abstract":["Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p < 0."],"journal":["Bone marrow transplantation"],"pubmed_title":["An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis."],"pmcid":["PMC8758206"],"funding_grant_id":["U01 AI126612","R01 HL130388","UG1 HL069246","P01 CA111412","R01 CA152108"],"pubmed_authors":["Zhang MJ","Bacher U","Yared JA","Michelis FV","Abdel-Azim H","Grunwald MR","Khera N","Palmisiano N","Gale RP","Olsson RF","Hourigan CS","Cairo M","Sharma A","Battiwalla M","Beitinjaneh A","Nathan S","Patel S","Wang TP","Milone G","Alkhateeb H","Copelan E","Chen K","Byrne M","DeFilipp Z","Bhatt VR","Bejanyan N","Kansagra A","Verdonck LF","Abid MB","Martino R","Kanakry CG","Kebriaei P","Castillo P","George B","Weisdorf D","Maakaron J","De Lima M","Krem MM","Mussetti A","Kharfan-Dabaja MA","Saad A","Solh M","Nishihori T","Cahn JY","Murthy HS","Assal A","Komanduri KV","Litzow M","McGuirk J","Aljurf M","Perez MAD","Baron F","Hildebrandt GC","Saber W","Jimenez Jimenez AM","Seo S","Hogan WJ","Mishra A","Lazaryan A","Elsawy M","Wirk B"],"additional_accession":[]},"is_claimable":false,"name":"An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis.","description":"Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p < 0.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-21T13:41:04.772Z","creation":"2025-02-18T23:36:19.737Z"},"accession":"S-EPMC8758206","cross_references":{"pubmed":["34584240"],"doi":["10.1038/s41409-021-01450-3"]}}